Aspira Women's Health (AWH) 10-Q 10 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity File Number	001-34810
Entity Registrant Name	Aspira Women’s Health Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0595156
Entity Address, Address Line One	12117 Bee Caves Road
Entity Address, Address Line Two	Building Three
Entity Address, Address Line Three	Suite 100
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78738
City Area Code	512
Local Phone Number	519-0400
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AWH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		112,296,388
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000926617
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 20,480	$ 37,180
Accounts receivable	1,112	1,027
Prepaid expenses and other current assets	1,173	1,624
Inventories	191	174
Total current assets	22,956	40,005
Property and equipment, net	438	464
Right-of-use assets	315	346
Restricted cash	250	250
Other assets	57	14
Total assets	24,016	41,079
Current liabilities:
Accounts payable	1,374	1,501
Accrued liabilities	5,059	5,299
Current portion of long-term debt	283	201
Short-term debt	260	779
Lease liability	68	60
Total current liabilities	7,044	7,840
Non-current liabilities:
Long-term debt	2,536	2,718
Lease liability	314	349
Total liabilities	9,894	10,907
Commitments and contingencies (Note 2)
Stockholders' equity:
Common stock, par value $0.001 per share, 150,000,000 shares authorized at June 30, 2022 and December 31, 2021; 112,296,388 and 112,138,741 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	112	112
Additional paid-in capital	503,249	501,788
Accumulated deficit	(489,239)	(471,728)
Total stockholders' equity	14,122	30,172
Total liabilities and stockholders' equity	$ 24,016	$ 41,079

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Condensed Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	112,296,388	112,138,741
Common stock, shares outstanding	112,296,388	112,138,741

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenue	$ 2,066	$ 1,799	$ 3,959	$ 3,295
Cost of revenue:
Cost of revenue	1,100	1,103	2,032	1,996
Gross profit	966	696	1,927	1,299
Operating expenses:
Research and development	1,410	1,471	2,758	2,343
Sales and marketing	3,580	4,018	8,077	7,126
General and administrative	4,196	3,279	8,559	5,788
Total operating expenses	9,186	8,768	19,394	15,257
Loss from operations	(8,220)	(8,072)	(17,467)	(13,958)
Interest (expense) income, net	(10)	3	(28)	(21)
Other (expense) income , net	(13)	995	(16)	985
Net loss	$ (8,243)	$ (7,074)	$ (17,511)	$ (12,994)
Net loss - basic	$ (0.07)	$ (0.06)	$ (0.16)	$ (0.12)
Net loss - diluted	$ (0.07)	$ (0.06)	$ (0.16)	$ (0.12)
Weighted average number of common shares used to compute basic net loss per common share	112,242,893	111,958,928	112,191,520	110,311,666
Weighted average number of common shares used to compute diluted net loss per common share	112,242,893	111,958,928	112,191,520	110,311,666
Product [Member]
Revenue:
Revenue	$ 2,018	$ 1,720	$ 3,853	$ 3,136
Cost of revenue:
Cost of revenue	1,036	839	1,893	1,494
Genetics [Member]
Revenue:
Revenue	48	79	106	159
Cost of revenue:
Cost of revenue	64	264	139	502
Cost Of Revenue [Member]
Operating expenses:
Stock-based compensation expense	35	54	87	88
Research And Development [Member]
Operating expenses:
Stock-based compensation expense	53	95	49	121
Sales And Marketing [Member]
Operating expenses:
Stock-based compensation expense	58	336	205	475
General And Administrative [Member]
Operating expenses:
Stock-based compensation expense	$ 464	$ 797	$ 1,107	$ 1,087

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance (in shares) at Dec. 31, 2020	104,619,876
Balance at Dec. 31, 2020	$ 105	$ 449,680	$ (440,066)	$ 9,719
Net loss			(5,920)	(5,920)
Common stock issued in conjunction with exercise of stock options (in shares)	196,976
Common stock issued in conjunction with exercise of stock options		317		317
Common stock issued in conjunction with public offering, net of issuance costs (in shares)	6,900,000
Common stock issued in conjunction with public offering, net of issuance costs	$ 7	47,713		47,720
Stock-based compensation expense		489		489
Balance (in shares) at Mar. 31, 2021	111,716,852
Balance at Mar. 31, 2021	$ 112	498,199	(445,986)	52,325
Balance (in shares) at Dec. 31, 2020	104,619,876
Balance at Dec. 31, 2020	$ 105	449,680	(440,066)	9,719
Net loss				(12,994)
Balance (in shares) at Jun. 30, 2021	112,058,034
Balance at Jun. 30, 2021	$ 112	499,786	(453,060)	46,838
Balance (in shares) at Mar. 31, 2021	111,716,852
Balance at Mar. 31, 2021	$ 112	498,199	(445,986)	52,325
Net loss			(7,074)	(7,074)
Common stock issued in conjunction with exercise of stock options (in shares)	305,090
Common stock issued in conjunction with exercise of stock options		304		304
Common stock issued for restricted stock awards (in shares)	36,092
Common stock issued for restricted stock awards		267		267
Common stock issued in conjunction with public offering, net of issuance costs		1		1
Stock-based compensation expense		1,015		1,015
Balance (in shares) at Jun. 30, 2021	112,058,034
Balance at Jun. 30, 2021	$ 112	499,786	(453,060)	46,838
Balance (in shares) at Dec. 31, 2021	112,138,741
Balance at Dec. 31, 2021	$ 112	501,788	(471,728)	30,172
Net loss			(9,268)	(9,268)
Common stock issued in conjunction with exercise of stock options (in shares)	3,000
Common stock issued in conjunction with exercise of stock options		2		2
Stock-based compensation expense		838		838
Balance (in shares) at Mar. 31, 2022	112,141,741
Balance at Mar. 31, 2022	$ 112	502,628	(480,996)	21,744
Balance (in shares) at Dec. 31, 2021	112,138,741
Balance at Dec. 31, 2021	$ 112	501,788	(471,728)	30,172
Net loss				(17,511)
Balance (in shares) at Jun. 30, 2022	112,296,388
Balance at Jun. 30, 2022	$ 112	503,249	(489,239)	14,122
Balance (in shares) at Mar. 31, 2022	112,141,741
Balance at Mar. 31, 2022	$ 112	502,628	(480,996)	21,744
Net loss			(8,243)	(8,243)
Common stock issued in conjunction with exercise of stock options (in shares)	20,000
Common stock issued in conjunction with exercise of stock options		11		11
Common stock issued for restricted stock awards (in shares)	134,647
Common stock issued for restricted stock awards		140		140
Stock-based compensation expense		470		470
Balance (in shares) at Jun. 30, 2022	112,296,388
Balance at Jun. 30, 2022	$ 112	$ 503,249	$ (489,239)	$ 14,122

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Cash Flows $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Cash flows from operating activities:
Net loss	$ (8,243)	$ (17,511)	$ (12,994)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense		4	32
Depreciation and amortization		128	172
Stock-based compensation expense		1,448	1,771
Loss on sale and disposal of property and equipment		3	1
Forgiveness of PPP loan			(1,006)
Changes in operating assets and liabilities:
Accounts receivable		(85)	(208)
Prepaid expenses and other assets		408	350
Inventories		(17)	(71)
Accounts payable, accrued liabilities and other liabilities		(855)	208
Net cash used in operating activities		(16,477)	(11,745)
Cash flows from investing activities:
Purchase of property and equipment		(105)	(136)
Net cash used in investing activities		(105)	(136)
Cash flows from financing activities:
Principal repayment of DECD loan		(131)	(99)
Proceeds from issuance of common stock from exercise of stock options		13	621
Proceeds from public offering			48,236
Payment of offering costs for public offering			(515)
Net cash (used in) provided by financing activities		(118)	48,243
Net (decrease) increase in cash, cash equivalents and restricted cash		(16,700)	36,362
Cash, cash equivalents and restricted cash, beginning of period		37,430	16,631
Cash, cash equivalents and restricted cash, end of period	20,730	20,730	52,993
Reconciliation to Condensed Consolidated Balance Sheet:
Cash and cash equivalents	20,480	20,480	52,993
Restricted cash	250	250
Unrestricted and restricted cash and cash equivalents	$ 20,730	20,730	52,993
Supplemental disclosure of cash flow information:
Cash paid during the period for interest		38	38
Supplemental disclosure of noncash investing and financing activities:
Net increase in right-of-use assets		$ (31)	(30)
Forgiveness of PPP loan			$ (1,006)

Organization, Basis Of Presenta

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	6 Months Ended
	Jun. 30, 2022
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Organization Aspira Women’s Health Inc., formerly known as Vermillion, Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company ”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) OVA1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy; (2) OVERA, a second-generation biomarker reflex intended to maintain OVA1’s high sensitivity while improving specificity; (3) OVA1plus, a reflex offering which uses OVA1 as the primary test and OVERA as a confirmation for OVA1 intermediate range results; (4) Aspira GenetiX, a genetic test for hereditary gynecologic cancer risk, with a core focus on hereditary female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers; and (5) Aspira Synergy, the Company’s testing platform and cloud service for testing. The Company plans to make OVA1, OVERA, OVA1plus and Aspira GenetiX and future technology available through Aspira Synergy. In 2021, the Company began entering into decentralized arrangements with large healthcare networks and large practices for its Aspira Synergy platform offering specialty and genetic testing solutions. Revenue from all of these sources is included in the results of operations in total revenue for the six months ended June 30, 2022. Liquidity As of June 30, 2022 , the Company had $ 20,480,000 of cash and cash equivalents (excluding restricted cash of $ 250,000 ), an accumulated deficit of approximately ($ 489,239,000 ), and w orking capital of $ 15,912,000 . For the six months ended June 30, 2022, the Company incurred a net loss of ($ 17,511,000 ) and used cash in operations of ($ 16,477,000 ). The Company has incurred significant net losses and negative cash flows from operations since inception and the Company also expects to continue to incur a net loss and negative cash flows from operations for 2022. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. The Company expects to raise capital through sources that may include public or private equity offerings, debt financings, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity, and that could have a material adverse effect on the Company’s business, results of operations and financial condition. On June 1, 2022, the Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). As provided in the Nasdaq rules, the Company has 180 calendar days, or until November 28, 2022, to regain compliance with the Minimum Bid Price Rule. The Company may achieve compliance during this period if the closing bid price of Aspira common stock is at least $1.00 per share for a minimum of 10 consecutive business days. If the Company fails to regain compliance on or prior to November 28, 2022, the Company may be eligible for an additional 180-calendar day compliance period. There is no assurance that the Company will be able to regain compliance by the November 28, 2022 deadline or the additional 180-calendar day extended deadline, and there is no assurance that the Company will otherwise maintain compliance with this or any of the other Nasdaq continued listing requirements. In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The novel coronavirus has since spread to over 100 countries, including every state in the United States. In March 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic, and the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel periodically throughout the pandemic. In order to reduce the impact of limitations on visiting physician offices due to closures and quarantines, the Company implemented other mechanisms for reaching physicians such as virtual sales representative meetings, Key Opinion Leader presentations, and increased digital sales and marketing. Patient enrollment for our planned clinical research studies has been slower than originally planned due to the impact of clinic closures and patients not seeking medical care in some states, which has led to delays in the completion of such studies. Given the uncertainties associated with potential resurgences of the COVID-19 pandemic, the Company is unable to estimate the extent of the impact of the COVID-19 pandemic on its operations or liquidity. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31 , 2021 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in Aspira’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 31, 2022. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. Significant Accounting Policies Revenue Recognition Product Revenue – OVA1, OVERA and OVA1plus: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Product revenue is recognized upon completion of the OVA1, OVERA or OVA1plus test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The effect of any change made to an estimated input component and, therefore revenue recognized, would be recorded as a change in estimate at the time of the change. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the period ended June 30, 2022, there were no adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the periods ended June 30, 2022 and 2021. Genetics Revenue – Aspira GenetiX : Under ASC 606, the Company’s genetics revenue is recognized upon completion of the Aspira GenetiX test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the Company has limited experience with such factors relating to Aspira GenetiX. Recent Accounting Pronouncements In June 2016 , the Financial Accounting Standards Board issued Accounting Standard Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. This ASU 2016-13 is scheduled to be effective in 2023 for smaller reporting companies. The Company is in the process of evaluating the impact of this standard on its consolidated financial statements.

Commitments And Contingencies

Commitments And Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments And Contingencies [Abstract]
Commitments And Contingencies	2. COMMITMENTS AND CONTINGENCIES Coronavirus Aid, Relief, and Economic Security (CARES) Act and Paycheck Protection Program Loan On May 1, 2020, the Company obtained the Paycheck Protection Program loan (the “PPP Loan”) from BBVA USA in the aggregate amount of approximately $ 1,006,000 . The Company applied for forgiveness of the PPP Loan in March 2021, and, effective May 27, 2021, the U.S. Small Business Administration confirmed the waiver of the Company’s repayment of the PPP Loan which was recognized as a gain in other income in 2021. The Company remains subject to an audit of the PPP loan. There is no assurance that the Company will not be required to repay all or a portion of the PPP Loan, as a result of any such audit. Loan Agreement On March 22, 2016, the Company entered into a loan agreement (as amended, the “DECD Loan Agreement”) with the State of Connecticut Department of Economic and Community Development (the “DECD”), pursuant to which the Company may borrow up to $ 4,000,000 from the DECD. The loan bears interest at a fixed rate of 2.0 % per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. The loan may be prepaid at any time without premium or penalty. An initial disbursement of $ 2,000,000 was made to the Company on April 15, 2016 under the DECD Loan Agreement. On December 3, 2020, the Company received a disbursement of the remaining $ 2,000,000 under the DECD Loan Agreement, as the Company had achieved the target employment milestone necessary to receive an additional $ 1,000,000 under the DECD Loan Agreement and the DECD determined to fund the remaining $ 1,000,000 under the DECD Loan Agreement after concluding that the required revenue target would likely have been achieved in the first quarter of 2020 in the absence of the impacts of COVID-19. Under the terms of the DECD Loan Agreement, the Company may be eligible for forgiveness of up to $ 1,500,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by December 31, 2022. Conversely, if the Company is either unable to retain 25 full-time employees with a specified average annual salary for a consecutive two-year period or does not maintain the Company’s Connecticut operations through March 22, 2026, the DECD may require early repayment of a portion or all of the loan plus a penalty of 5 % of the total funded loan. The carrying value approximates fair value, as the interest represents market prices for similar types of borrowing arrangements. Long-term debt consisted of the following: June 30, December 31, 2022 2021 (in thousands) DECD loan, net of issuance costs $ 2,819 $ 2,919 Less: Current portion, net of issuance costs ( 283 ) ( 201 ) Total long-term debt, net of issuance costs $ 2,536 $ 2,718 As of June 30, 2022, the annual amounts of future minimum principal payments due under the Company’s contractual obligation are shown in the table below. Unamortized debt issuance costs for the DECD loan were $ 13,000 . Debt related to the insurance promissory note of $ 260,000 , as described below, is not included in the following table due to the insurance promissory note being cancelable. Payments Due by Period (in thousands) Total 2022 2023 2024 2025 2026 Thereafter DECD Loan $ 2,832 $ 103 $ 406 $ 452 $ 461 $ 341 $ 1,069 Total $ 2,832 $ 103 $ 406 $ 452 $ 461 $ 341 $ 1,069 Accrued Liabilities The following table describes the principal components of accrued liabilities on the Company’s condensed consolidated b alance sheet as of: June 30, December 31, (in thousands) 2022 2021 Payroll and benefits related expenses $ 2,786 $ 2,652 Collaboration and research agreements expenses 429 382 Professional services 1,221 1,992 Other accrued liabilities 623 273 Total accrued liabilities $ 5,059 $ 5,299 Insurance Notes During 2021, the Company entered into an insurance promissory note for the payment of insurance premiums at an interest rate of 3.74 %, with an aggregate principal amount outstanding of approximately $ 260,000 and $ 779,000 as of June 30, 2022 and December 31, 2021, respectively. This note is payable in ten monthly installments with a maturity date of October 1, 2022 and has no financial or operational covenants. Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the Clinical Laboratory Improvements Amendments of 1988 (“CLIA”) laboratory used by Aspira Labs, Inc., is located in Austin, Texas, and the CLIA laboratory used for research and development services is located in Trumbull, Connecticut. In October 2021, the Company renewed the Austin, Texas lease for one additional year. The Company’s renewed lease expires on January 31, 2023, with no automatic renewal or renewal option. The Company’s Texas lease has a term of 12 months. The Company recognized the lease payments in profit and loss on a straight-line basis over the term of the lease, and variable lease payments in the period in which the obligation for the payments was incurred. In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately $ 596,000 . In September 2020, the Company exercised the renewal option for its Trumbull, Connecticut lease. The Company’s renewed lease expires on June 30, 2026 , with a five year renewal option. The Company is not reasonably certain that it will exercise the five year renewal option beginning on July 1, 2026. The expense associated with these operating leases for the three and six months ended June 30, 2022 and 2021 is shown in the table below (in thousands). Three Months Ended June 30, Lease Cost Classification 2022 2021 Operating rent expense Cost of revenue $ 19 $ 15 Research and development 7 13 Sales and marketing 10 6 General and administrative 17 17 Variable rent expense Cost of revenue $ 10 $ 8 Research and development 5 9 Sales and marketing 9 7 General and administrative 17 14 Six Months Ended June 30, Lease Cost Classification 2022 2021 Operating rent expense Cost of revenue $ 39 $ 28 Research and development 14 22 Sales and marketing 19 17 General and administrative 33 35 Variable rent expense Cost of revenue $ 20 $ 15 Research and development 11 13 Sales and marketing 18 19 General and administrative 35 30 Based on the Company’s leases as of June 30, 2022, the table below sets forth the approximate future lease payments related to operating leases with initial terms of one year or more (in thousands). 2022 $ 50 2023 106 2024 116 2025 124 2026 64 Total Operating Lease Payments 460 Less: Interest ( 78 ) Present Value of Lease Liabilities $ 382 Weighted- average lease term and discount rate were as follows: Weighted-average remaining lease term (in years) 4.0 Weighted-average discount rate 9.32 % Non-cancelable Royalty Obligations The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human disease. Under the terms of the amended research collaboration agreement, Aspira is required to pay the greater of 4 % royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $ 57,500 . Royalty expense for the three months ended June 30, 2022 and 2021 totaled $ 81,000 and $ 69,000 , respectively, and royalty expense for the six months ended June 30, 2022 and 2021 totaled $ 154,000 and $ 126,000 , respectively, as recorded in cost of revenue in the condensed consolidated statements of operations. Commercial Reorganization During the three months ended March 31, 2022, the Company executed a commercial reorganization resulting in the separation of a number of employees. The organizational changes resulted in the recording within the condensed consolidated statement of operations in sales and marketing, research and development and general and administrative expenses of one-time severance, separation, and settlement charges of approximately $ 1,284,000 . These amounts have been partially offset by insurance reimbursement of $ 523,000 , of which $ 433,000 has been received during the six months ended June 30, 2022 and $ 90,000 is included in Prepaid expenses and other current assets on the condensed consolidated balance sheet as of June 30, 2022. As of June 30, 2022, remaining unpaid estimated charges in the amount of $ 90,000 are included in Accrued liabilities on the condensed consolidated balance sheet. The Company paid the remaining charges in July 2022, and the Company expects to be reimbursed by the insurance company within 3 months of payment. Contingent Liabilities From time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations. The Company establishes reserves for specific liabilities in connection with legal actions that management deems to be probable and estimable. The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity [Abstract]
Stockholders' Equity	3. STOCKHOLDERS’ EQUITY 2021 Public Offering On February 4, 2021, the Company entered into an underwriting agreement (the “2021 Underwriting Agreement”) with William Blair & Company, L.L.C. and Truist Securities, Inc., as representatives of several underwriters (the “2021 Underwriters”), in connection with the underwritten public offering of 6,000,000 shares of Aspira common stock at a price to the public of $ 7.50 per share. The 2021 Underwriters purchased these 6,000,000 shares at the public offering price per share, less the underwriting discount of $ 0.4875 per share. Under the 2021 Underwriting Agreement, the Company granted the 2021 Underwriters an option to purchase up to an additional 900,000 shares of Aspira common stock at the public offering price, less the underwriting discount of $ 0.4875 per share. On February 5, 2021, the 2021 Underwriters notified the Company that they were exercising this option in connection with the closing of the 2021 Offering. The 2021 Offering, including the additional 900,000 shares of Aspira common stock, closed on February 8, 2021 and resulted in net proceeds to the Company of approximately $ 47,720,000 , after deducting underwriting discounts and offering expenses of $ 516,000 . There was a change in estimate in the third quarter of 2021 in the amount of $ 138,000 relating to an expense reversal of offering costs. 2019 Stock Incentive Plan At the Company’s 2019 annual meeting of stockholders, the Company’s stockholders approved the Vermillion, Inc. 2019 Stock Incentive Plan, the name of which was subsequently changed to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan (the “2019 Plan”). The purposes of the 2019 Plan are (i) to align the interests of the Company’s stockholders and recipients of awards under the 2019 Plan by increasing the proprietary interest of such recipients in the Company’s growth and success; (ii) to advance the interests of the Company by attracting and retaining non-employee directors, officers, other employees, consultants, independent contractors and agents; and (iii) to motivate such persons to act in the long-term best interests of the Company and its stockholders. The 2019 Plan allows the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to participants. Subject to the terms and conditions of the 2019 Plan, the initial number of shares authorized for grants under the 2019 Plan is 10,492,283 . To the extent an equity award granted under the 2019 Plan expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares of common stock subject to such award will become available for future grant under the 2019 Plan. As of June 30, 2022, 10,087,299 shares of Aspira common stock were subject to outstanding stock options, and 298,500 shares of Aspira common stock were subject to unvested restricted stock awards and a total of 3,336,361 shares of Aspira common stock were reserved for issuance under the 2019 Plan. Stock-Based Compensation During the three months ended March 31, 2022, the Company granted the following awards under the 2019 Plan. In addition, assumptions included in the fair value per share calculations were expected terms of one to four years , one- to five- year treasury interest rates of 1.38 % to 3.28 % and market close prices ranging from $ 1.04 to $ 1.08 . The Company recorded $ 334,000 in forfeitures for the three months ended March 31, 2022. Grant Date Number of Shares Type of Award Exercise Price / Share Fair Value / Share 1/28/2022 222,000 Options $ 1.08 $ 0.70 3/1/2022 5,000 Options $ 1.05 $ 0.31 3/31/2022 1,706,282 Options $ 1.04 $ 0.51 3/31/2022 269,297 Restricted Stock Units $ - $ - 2,202,579 During the three months ended June 30, 2022, the Company granted the following awards under the 2019 Plan. In addition, assumptions included in the fair value per share calculations were expected terms of one to two years , one- to five-year treasury interest rates of 1.72 % to 3.13 % and market close prices ranging from $ 0.52 to $ 1.05 . The Company recorded $ 109,000 in forfeitures for the three months ended June 30, 2022. Grant Date Number of Shares Type of Award Exercise Price Fair Value / Share 4/1/2022 5,000 Options $ 1.05 $ 0.33 5/2/2022 5,000 Options $ 0.70 $ 0.22 5/19/2022 60,000 Options $ 0.55 $ 0.28 6/1/2022 5,000 Options $ 0.56 $ 0.22 6/23/2022 15,000 Options $ 0.52 $ 0.21 6/23/2022 78,000 Options $ 0.52 $ 0.27 6/23/2022 83,799 Options $ 0.52 $ 0.36 6/23/2022 169,043 Restricted Stock Units $ - $ - 420,842 The allocation of employee stock-based compensation expense by functional area for the three and six months ended June 30, 2022 and 2021 was as follows: Three Months Ended Six Months Ended June 30, June 30, (in thousands) 2022 2021 2022 2021 Cost of revenue $ 33 $ 48 $ 79 $ 79 Research and development 20 93 ( 10 ) 118 Sales and marketing 58 325 205 464 General and administrative 441 601 1,017 791 Total $ 552 $ 1,067 $ 1,291 $ 1,452

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2022
Loss Per Share [Abstract]
Loss Per Share	4. LOSS PER SHARE The Company calculates basic loss per share using the weighted average number of shares of Aspira common stock outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the weighted average number of shares of Aspira common stock outstanding and excludes the effects of 10,385,799 and 10,272,785 potential shares of Aspira common stock as of June 30, 2022 and 2021, respectively, that are anti-dilutive. Potential shares of Aspira common stock include incremental shares of Aspira common stock issuable upon the exercise of stock options and unvested restricted stock units.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	5. SUBSEQUENT EVENTS On August 8, 2022, the Company entered into a sponsored research agreement with Harvard’s Dana-Farber Cancer Institute (“DFCI”), Brigham and Women’s Hospital (“BWH”), and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating microRNAs and proteins. This collaboration is expected to accelerate the Company’s development and commercialization of future endometriosis products, such as EndoCheck. Under the terms of the agreement, payments of approximately $ 1.2 million will become due from the Company to the counterparties upon the achievement of certain milestones in 2022 and 2023 as follows: 68 % will become payable within seven days of the execution of the agreement, 15 % will become payable upon completion of certain milestones estimated to occur in the fourth quarter of 2022, and 17 % will become payable upon completion of certain milestones estimated to occur in the second quarter of 2023 .

Organization, Basis Of Presen_2

Organization, Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Policy)	6 Months Ended
	Jun. 30, 2022
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Aspira Women’s Health Inc., formerly known as Vermillion, Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company ”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) OVA1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy; (2) OVERA, a second-generation biomarker reflex intended to maintain OVA1’s high sensitivity while improving specificity; (3) OVA1plus, a reflex offering which uses OVA1 as the primary test and OVERA as a confirmation for OVA1 intermediate range results; (4) Aspira GenetiX, a genetic test for hereditary gynecologic cancer risk, with a core focus on hereditary female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers; and (5) Aspira Synergy, the Company’s testing platform and cloud service for testing. The Company plans to make OVA1, OVERA, OVA1plus and Aspira GenetiX and future technology available through Aspira Synergy. In 2021, the Company began entering into decentralized arrangements with large healthcare networks and large practices for its Aspira Synergy platform offering specialty and genetic testing solutions. Revenue from all of these sources is included in the results of operations in total revenue for the six months ended June 30, 2022.
Liquidity	Liquidity As of June 30, 2022 , the Company had $ 20,480,000 of cash and cash equivalents (excluding restricted cash of $ 250,000 ), an accumulated deficit of approximately ($ 489,239,000 ), and w orking capital of $ 15,912,000 . For the six months ended June 30, 2022, the Company incurred a net loss of ($ 17,511,000 ) and used cash in operations of ($ 16,477,000 ). The Company has incurred significant net losses and negative cash flows from operations since inception and the Company also expects to continue to incur a net loss and negative cash flows from operations for 2022. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. The Company expects to raise capital through sources that may include public or private equity offerings, debt financings, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity, and that could have a material adverse effect on the Company’s business, results of operations and financial condition. On June 1, 2022, the Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). As provided in the Nasdaq rules, the Company has 180 calendar days, or until November 28, 2022, to regain compliance with the Minimum Bid Price Rule. The Company may achieve compliance during this period if the closing bid price of Aspira common stock is at least $1.00 per share for a minimum of 10 consecutive business days. If the Company fails to regain compliance on or prior to November 28, 2022, the Company may be eligible for an additional 180-calendar day compliance period. There is no assurance that the Company will be able to regain compliance by the November 28, 2022 deadline or the additional 180-calendar day extended deadline, and there is no assurance that the Company will otherwise maintain compliance with this or any of the other Nasdaq continued listing requirements. In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The novel coronavirus has since spread to over 100 countries, including every state in the United States. In March 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic, and the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel periodically throughout the pandemic. In order to reduce the impact of limitations on visiting physician offices due to closures and quarantines, the Company implemented other mechanisms for reaching physicians such as virtual sales representative meetings, Key Opinion Leader presentations, and increased digital sales and marketing. Patient enrollment for our planned clinical research studies has been slower than originally planned due to the impact of clinic closures and patients not seeking medical care in some states, which has led to delays in the completion of such studies. Given the uncertainties associated with potential resurgences of the COVID-19 pandemic, the Company is unable to estimate the extent of the impact of the COVID-19 pandemic on its operations or liquidity.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31 , 2021 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in Aspira’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 31, 2022. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.
Revenue Recognition	Revenue Recognition Product Revenue – OVA1, OVERA and OVA1plus: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Product revenue is recognized upon completion of the OVA1, OVERA or OVA1plus test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The effect of any change made to an estimated input component and, therefore revenue recognized, would be recorded as a change in estimate at the time of the change. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the period ended June 30, 2022, there were no adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the periods ended June 30, 2022 and 2021. Genetics Revenue – Aspira GenetiX : Under ASC 606, the Company’s genetics revenue is recognized upon completion of the Aspira GenetiX test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the Company has limited experience with such factors relating to Aspira GenetiX.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016 , the Financial Accounting Standards Board issued Accounting Standard Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. This ASU 2016-13 is scheduled to be effective in 2023 for smaller reporting companies. The Company is in the process of evaluating the impact of this standard on its consolidated financial statements.

Commitments And Contingencies (

Commitments And Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments And Contingencies [Abstract]
Schedule of Long-term Debt	June 30, December 31, 2022 2021 (in thousands) DECD loan, net of issuance costs $ 2,819 $ 2,919 Less: Current portion, net of issuance costs ( 283 ) ( 201 ) Total long-term debt, net of issuance costs $ 2,536 $ 2,718
Annual Amounts of Future Minimum Principal Payments Due Under Certain Contractual Obligations	Payments Due by Period (in thousands) Total 2022 2023 2024 2025 2026 Thereafter DECD Loan $ 2,832 $ 103 $ 406 $ 452 $ 461 $ 341 $ 1,069 Total $ 2,832 $ 103 $ 406 $ 452 $ 461 $ 341 $ 1,069
Components Of Accrued Liabilities	June 30, December 31, (in thousands) 2022 2021 Payroll and benefits related expenses $ 2,786 $ 2,652 Collaboration and research agreements expenses 429 382 Professional services 1,221 1,992 Other accrued liabilities 623 273 Total accrued liabilities $ 5,059 $ 5,299
Expense Associated with Operating Leases	Three Months Ended June 30, Lease Cost Classification 2022 2021 Operating rent expense Cost of revenue $ 19 $ 15 Research and development 7 13 Sales and marketing 10 6 General and administrative 17 17 Variable rent expense Cost of revenue $ 10 $ 8 Research and development 5 9 Sales and marketing 9 7 General and administrative 17 14 Six Months Ended June 30, Lease Cost Classification 2022 2021 Operating rent expense Cost of revenue $ 39 $ 28 Research and development 14 22 Sales and marketing 19 17 General and administrative 33 35 Variable rent expense Cost of revenue $ 20 $ 15 Research and development 11 13 Sales and marketing 18 19 General and administrative 35 30
Future Lease Payments Related to Operating Leases	2022 $ 50 2023 106 2024 116 2025 124 2026 64 Total Operating Lease Payments 460 Less: Interest ( 78 ) Present Value of Lease Liabilities $ 382
Weighted-Average Lease Term and Discount Rate	Weighted-average remaining lease term (in years) 4.0 Weighted-average discount rate 9.32 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity [Abstract]
Schedule of Awards Granted	During the three months ended March 31, 2022, the Company granted the following awards under the 2019 Plan. In addition, assumptions included in the fair value per share calculations were expected terms of one to four years , one- to five- year treasury interest rates of 1.38 % to 3.28 % and market close prices ranging from $ 1.04 to $ 1.08 . The Company recorded $ 334,000 in forfeitures for the three months ended March 31, 2022. Grant Date Number of Shares Type of Award Exercise Price / Share Fair Value / Share 1/28/2022 222,000 Options $ 1.08 $ 0.70 3/1/2022 5,000 Options $ 1.05 $ 0.31 3/31/2022 1,706,282 Options $ 1.04 $ 0.51 3/31/2022 269,297 Restricted Stock Units $ - $ - 2,202,579 During the three months ended June 30, 2022, the Company granted the following awards under the 2019 Plan. In addition, assumptions included in the fair value per share calculations were expected terms of one to two years , one- to five-year treasury interest rates of 1.72 % to 3.13 % and market close prices ranging from $ 0.52 to $ 1.05 . The Company recorded $ 109,000 in forfeitures for the three months ended June 30, 2022. Grant Date Number of Shares Type of Award Exercise Price Fair Value / Share 4/1/2022 5,000 Options $ 1.05 $ 0.33 5/2/2022 5,000 Options $ 0.70 $ 0.22 5/19/2022 60,000 Options $ 0.55 $ 0.28 6/1/2022 5,000 Options $ 0.56 $ 0.22 6/23/2022 15,000 Options $ 0.52 $ 0.21 6/23/2022 78,000 Options $ 0.52 $ 0.27 6/23/2022 83,799 Options $ 0.52 $ 0.36 6/23/2022 169,043 Restricted Stock Units $ - $ - 420,842
Allocation of Employee and Director Stock-Based Compensation Expense by Functional Area	Three Months Ended Six Months Ended June 30, June 30, (in thousands) 2022 2021 2022 2021 Cost of revenue $ 33 $ 48 $ 79 $ 79 Research and development 20 93 ( 10 ) 118 Sales and marketing 58 325 205 464 General and administrative 441 601 1,017 791 Total $ 552 $ 1,067 $ 1,291 $ 1,452

Organization, Basis Of Presen_3

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Cash and cash equivalents	$ 20,480,000		$ 52,993,000		$ 20,480,000	$ 52,993,000	$ 37,180,000
Restricted cash	250,000				250,000		250,000
Accumulated deficit	(489,239,000)				(489,239,000)		$ (471,728,000)
Working capital	15,912,000				15,912,000
Net loss	(8,243,000)	$ (9,268,000)	(7,074,000)	$ (5,920,000)	(17,511,000)	(12,994,000)
Net cash used in operating activities					(16,477,000)	(11,745,000)
Receivable impairment	$ 0		$ 0		$ 0	$ 0

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details)			3 Months Ended			6 Months Ended
	Dec. 03, 2020 USD ($)	Apr. 15, 2016 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) employee	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	May 01, 2020 USD ($)	Oct. 31, 2015 USD ($)
Commitments And Contingencies [Line Items]
Severance charge				$ 1,284,000
Insurance reimbursement						$ 523,000
Insurance reimbursement received						433,000
Insurance reimbursement not paid			$ 90,000			90,000
Unpaid estimated charges			90,000			$ 90,000
Royalty expense			$ 81,000		$ 69,000
Austin, Texas facility
Commitments And Contingencies [Line Items]
Operating lease term			12 months			12 months
Lease renewal term			1 year			1 year
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Leasehold improvements										$ 596,000
Lease expiration date						Jun. 30, 2026
Lease renewal term			5 years			5 years
DECD Loan [Member]
Commitments And Contingencies [Line Items]
Aggregate amount of loan			$ 4,000,000			$ 4,000,000
Debt instrument interest rate			2%			2%
Maturity date						Apr. 15, 2026
Proceeds from loan	$ 2,000,000	$ 2,000,000
Maximum loan forgiveness amount under loan agreement						$ 1,500,000
Number of full time employees expected to be retained under loan agreement | employee						25
Consecutive period full times employees with specified average annual salary under loan agreement						2 years
Percentage of penalty on total loan fund included in loan agreement						5%
Cancelable insurance promissory note			$ 260,000			$ 260,000
DECD Loan [Member] | Loan Agreement Target Employment Milestone [Member]
Commitments And Contingencies [Line Items]
Proceeds from loan	1,000,000
DECD Loan [Member] | Loan Agreement Required Revenue Target [Member]
Commitments And Contingencies [Line Items]
Proceeds from loan	$ 1,000,000
PPP Loan [Member]
Commitments And Contingencies [Line Items]
Aggregate amount of loan									$ 1,006,000
Insurance Promissory Notes [Member]
Commitments And Contingencies [Line Items]
Debt instrument interest rate								3.74%
Aggregate principal amount outstanding			260,000			$ 260,000		$ 779,000
Johns Hopkins University School Of Medicine [Member]
Commitments And Contingencies [Line Items]
Percent of royalty paid						4%
Minimum royalty payment						$ 57,500
Royalty expense						154,000	$ 126,000
DECD [Member]
Commitments And Contingencies [Line Items]
Unamortized debt issuance costs			$ 13,000			$ 13,000

Commitments And Contingencies_3

Commitments And Contingencies (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instruments [Abstract]
DECD loan. net of issuance costs	$ 2,819	$ 2,919
Less: Current portion, net of issuance costs	(283)	(201)
Total long-term debt, net of issuance costs	$ 2,536	$ 2,718

Commitments And Contingencies_4

Commitments And Contingencies (Annual Amounts of Future Minimum Principal Payments Due Under Certain Contractual Obligations) (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Other Commitments [Line Items]
Contractual obligation, 2022	$ 103
Contractual obligation, 2023	406
Contractual obligation, 2024	452
Contractual obligation, 2025	461
Contractual obligation, 2026	341
Contractual obligation, Thereafter	1,069
Total	2,832
DECD Loan [Member]
Other Commitments [Line Items]
Contractual obligation, 2022	103
Contractual obligation, 2023	406
Contractual obligation, 2024	452
Contractual obligation, 2025	461
Contractual obligation, 2026	341
Contractual obligation, Thereafter	1,069
Total	$ 2,832

Commitments And Contingencies_5

Commitments And Contingencies (Components Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Commitments And Contingencies [Abstract]
Payroll and benefits related expenses	$ 2,786	$ 2,652
Collaboration and research agreements expenses	429	382
Professional services	1,221	1,992
Other accrued liabilities	623	273
Total accrued liabilities	$ 5,059	$ 5,299

Commitments And Contingencies_6

Commitments And Contingencies (Expense Associated with Operating Leases) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cost Of Revenue [Member]
Operating rent expense	$ 19	$ 15	$ 39	$ 28
Variable rent expense	10	8	20	15
Research And Development [Member]
Operating rent expense	7	13	14	22
Variable rent expense	5	9	11	13
Sales And Marketing [Member]
Operating rent expense	10	6	19	17
Variable rent expense	9	7	18	19
General And Administrative [Member]
Operating rent expense	17	17	33	35
Variable rent expense	$ 17	$ 14	$ 35	$ 30

Commitments And Contingencies_7

Commitments And Contingencies (Future Lease Payments Related to Operating Leases) (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 50
2023	106
2024	116
2025	124
2026	64
Total Operating Lease Payments	460
Less: Interest	(78)
Present Value of Lease Liabilities	$ 382

Commitments And Contingencies_8

Commitments And Contingencies (Weighted-Average Lease Term and Discount Rate) (Details)	Jun. 30, 2022
Leases [Abstract]
Weighted-average remaining lease term (in years)	4 years
Weighted-average discount rate	9.32%

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended				6 Months Ended
	Feb. 08, 2021	Feb. 04, 2021	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds after deducting underwriting discounts and offering expenses								$ 48,236
Offering cost								$ 515
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares authorized for grants									10,492,283
Share based compensation shares reserved for issuance			3,336,361				3,336,361
Interest rate, maximum			3.13%				3.28%
Interest rate, minimum			1.72%				1.38%
Forfeitures amount			$ 109	$ 334
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market close prices			$ 1.05				$ 1.05
Stock options granted, average exercise price			$ 1.05				$ 1.05
Maximum [Member] | 2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives (years)			2 years				4 years
Market close prices				$ 1.08
Stock options granted, average exercise price				$ 1.08
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market close prices			$ 0.52				$ 0.52
Stock options granted, average exercise price			$ 0.52				$ 0.52
Minimum [Member] | 2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives (years)			1 year				1 year
Market close prices			$ 1.04				$ 1.04
Stock options granted, average exercise price			$ 1.04				$ 1.04
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued						6,900,000
2021 Public Offering [Member] | Restatement Adjustment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering cost					$ (138)
2021 Public Offering [Member] | Common Stock | 2021 Underwriters Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price per share		$ 0.4875
Expenses related to stock issuance	$ 516
Underwriting agreement, shares		6,000,000
Underwriting agreement, per share		$ 7.50
Common stock shares issued	900,000	6,000,000
Underwriting commitments additional shares offered		900,000
Net proceeds after deducting underwriting discounts and offering expenses	$ 47,720
Common Stock Subject to Outstanding Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance			10,087,299				10,087,299
Common Stock Subject to Unvested Restricted Stock Awards [Member] | 2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance			298,500				298,500

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule of Awards Granted) (Details) - 2019 Stock Incentive Plan [Member] - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	420,842	2,202,579
1/28/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares		222,000
Exercise Price / Share		$ 1.08
Fair Value / Share		$ 0.70
3/1/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares		5,000
Exercise Price / Share		$ 1.05
Fair Value / Share		$ 0.31
3/31/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares		1,706,282
Exercise Price / Share		$ 1.04
Fair Value / Share		$ 0.51
3/31/2022 [Member] | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares		269,297
4/1/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	5,000
Exercise Price / Share	$ 1.05
Fair Value / Share	$ 0.33
5/2/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	5,000
Exercise Price / Share	$ 0.70
Fair Value / Share	$ 0.22
5/19/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	60,000
Exercise Price / Share	$ 0.55
Fair Value / Share	$ 0.28
6/1/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	5,000
Exercise Price / Share	$ 0.56
Fair Value / Share	$ 0.22
6/23/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	15,000
Exercise Price / Share	$ 0.52
Fair Value / Share	$ 0.21
6/23/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	78,000
Exercise Price / Share	$ 0.52
Fair Value / Share	$ 0.27
6/23/2022 [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	83,799
Exercise Price / Share	$ 0.52
Fair Value / Share	$ 0.36
6/23/2022 [Member] | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares	169,043

Stockholders' Equity (Allocatio

Stockholders' Equity (Allocation of Employee and Director Stock-Based Compensation Expense by Functional Area) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 35	$ 54	$ 87	$ 88
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	53	95	49	121
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	58	336	205	475
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	464	797	1,107	1,087
Employee Stock-Based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	552	1,067	1,291	1,452
Employee Stock-Based Compensation [Member] | Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	33	48	79	79
Employee Stock-Based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	20	93	(10)	118
Employee Stock-Based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	58	325	205	464
Employee Stock-Based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 441	$ 601	$ 1,017	$ 791

Loss Per Share (Details)

Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Potential Shares of Aspira Common Stock [Member]
Antidilutive securities excluded from computation of earnings per share	10,385,799	10,272,785

Subsequent Events (Details)

Subsequent Events (Details) - Sponsored Research Agreement [Member] - USD ($) $ in Millions			3 Months Ended
	Aug. 15, 2022	Aug. 08, 2022	Jun. 30, 2023	Dec. 31, 2022
Forecast [Member]
Subsequent Event [Line Items]
Agreement amount, percent payable	68%		17%	15%
Subsequent Event
Subsequent Event [Line Items]
Agreement amount		$ 1.2